Payment overview · 2025
General Payments
$1,808.27
89 reported records · 22 companies
Healthcare provider profile · identity verified
Leonard N. Glade, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW ORLEANS, LA · NPI 1184676744
Verified facts
What the public records show
CMS Open Payments records show Leonard N. Glade, M.D. received $1,808.27 in general payments during 2025 across 89 reported records.
GENZYME CORPORATION accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nucala, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $261.18 | 14.4% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $254.81 | 14.1% | 20 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $231.71 | 12.8% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $169.69 | 9.4% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.59 | 8.2% | 7 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $125.70 | 7.0% | 6 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $67.91 | 3.8% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $67.79 | 3.8% | 3 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $64.46 | 3.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.05 | 3.4% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.29 | 2.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.13 | 2.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.60 | 2.5% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $34.42 | 1.9% | 2 | 2025 |
| Pinnacle Biologics, Inc | Unresolved — no canonical attribution shown | $32.26 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.93 | 1.7% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $27.60 | 1.5% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $20.20 | 1.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.55 | 1.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.12 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.68 | 1.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.60 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,808.27 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $492.89 | 19 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $181.70 | 14 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $125.70 | 6 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $73.57 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.11 | 6 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $67.91 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $64.52 | 3 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $64.46 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.05 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $50.29 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $42.98 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| Photofrin Normalized: photofrin |
Drug | Pinnacle Biologics, Inc | $32.26 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $30.32 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.93 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $27.60 | 1 | 2025 |
Source payment records
|
|||||
| CONFIRM RX Normalized: confirm rx |
Device | Abbott Laboratories | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| General - Thrombectomy Normalized: general thrombectomy |
Device | Boston Scientific Corporation | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| MULTI-LINK VISION Normalized: multi link vision |
Device | Abbott Laboratories | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $7.94 | 1 | 2025 |
Source payment records
|
|||||
| ACCENT Normalized: accent |
Device | Abbott Laboratories | $4.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUCALA nucala |
2025 | Nucala | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 256 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
177 | 41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
256 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 616 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 310 | 78 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 256 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 61 |
| Breo Ellipta | Fluticasone/Vilanterol | 223 | 44 |
| Prednisone | Prednisone | 182 | 97 |
| Symbicort | Budesonide/Formoterol Fumarate | 177 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 47 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 153 | 26 |
| Montelukast Sodium | Montelukast Sodium | 153 | 48 |
| Lorazepam | Lorazepam | 136 | 31 |
| Metformin Hcl | Metformin Hcl | 133 | 37 |
| Losartan Potassium | Losartan Potassium | 129 | 38 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 116 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 111 | 33 |
| Eliquis | Apixaban | 106 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 31 |
| Gabapentin | Gabapentin | 102 | 31 |
| Omeprazole | Omeprazole | 102 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 67 |
| Donepezil Hcl | Donepezil Hcl | 90 | 17 |
| Lisinopril | Lisinopril | 90 | 24 |
| Alprazolam | Alprazolam | 89 | 14 |
| Furosemide | Furosemide | 89 | 31 |
| Potassium Chloride | Potassium Chloride | 88 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 16 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 84 | 13 |
| Famotidine | Famotidine | 81 | 14 |
| Tramadol Hcl | Tramadol Hcl | 77 | 15 |
| Carvedilol | Carvedilol | 76 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 71 | 24 |
| Pregabalin | Pregabalin | 67 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 66 | suppressed |
| Memantine Hcl | Memantine Hcl | 64 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | suppressed |
| Jardiance | Empagliflozin | 60 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | suppressed |
| Nifedipine Er | Nifedipine | 52 | 12 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Allopurinol | Allopurinol | 49 | suppressed |
| Irbesartan | Irbesartan | 44 | 14 |
| Azithromycin | Azithromycin | 42 | 18 |
| Synthroid | Levothyroxine Sodium | 40 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Tadalafil | Tadalafil | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Rifampin | Rifampin | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Dupixent Pen | Dupilumab | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Nucala | Mepolizumab | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Bosentan | Bosentan | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,808.27 · 89 records | GENZYME CORPORATION | ACCENT, ACCRUFER, ACTHAR, AVEIR, BREZTRI, CONFIRM RX, DUPIXENT, FASENRA, GALLANT, General - Thrombectomy, JOT DX, JYNARQUE, Kerendia, Labosys, MULTI-LINK VISION, NEFFY, NEXLETOL, NUCALA, Ohtuvayre, Ozempic, PURIFIED CORTROPHIN GEL, Photofrin, REPATHA, Ranger, TARPEYO, TEZSPIRE, TRELEGY ELLIPTA, Vafseo, Vest Therapy Und, WATCHMAN, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nucala play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error